Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07 2022 - 8:15AM
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a
clinical-stage pharmaceutical company focused on developing next
generation oral and IV antibiotics to treat infections caused by
multi-drug resistant pathogens in both community and hospital
settings, today announced that Corey Fishman, Chief Executive
Officer, and Judy Matthews, Chief Financial Officer, will provide a
company overview and business update at the H.C. Wainwright 24th
Annual Hybrid Global Investment Conference at 12:00pm(ET) on
Wednesday, September 14, 2022. Management will also host investor
meetings on September 13-14, 2022.
Following the conference, a webcast of the presentation will be
available to view for 90 days by visiting the "Investors" section
of the Company's website under the "Events and Presentations" tab
at www.iterumtx.com.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage
pharmaceutical company dedicated to developing differentiated
anti-infectives aimed at combatting the global crisis of multi-drug
resistant pathogens to significantly improve the lives of people
affected by serious and life-threatening diseases around the world.
Iterum Therapeutics is advancing its first compound, sulopenem, a
novel penem anti-infective compound, in Phase 3 clinical
development with an oral formulation and IV formulation. Sulopenem
has demonstrated potent in vitro activity against a wide variety of
gram-negative, gram-positive and anaerobic bacteria resistant to
other antibiotics. Iterum Therapeutics has received Qualified
Infectious Disease Product (QIDP) and Fast Track designations for
its oral and IV formulations of sulopenem in seven indications.
Investor Contact:Judy
MatthewsChief Financial Officer 312-778-6073IR@iterumtx.com
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Apr 2023 to Apr 2024